Press "Enter" to skip to content

New patent for Takeda Pharms drug VYVANSE

0
Copyright © DrugPatentWatch. Originally published at New patent for Takeda Pharms drug VYVANSE

Annual Drug Patent Expirations for VYVANSE
Annual Drug Patent Expirations for VYVANSE

Vyvanse is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from one supplier. There are eighteen patents protecting this drug and one Paragraph IV challenge.

VYVANSE drug price trends.

Drug patent litigation for VYVANSE.

This drug has one hundred and forty-four patent family members in twenty-seven countries.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. One supplier is listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Takeda Pharms drug VYVANSE
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions